The antitrust case against Teva survives on a narrower set of claims, allowing discovery to proceed on the DAW campaign, PBM agreements, and 2020 reclassification. The dismissal of multiple claims reduces the potential recovery but the core theory remains viable. Monitor for discovery milestones, summary judgment motions, and potential settlement discussions. The litigation timeline is likely years, and the stock may not react strongly given the interlocutory nature of the ruling.
Price Chart
Executive Summary
The District Court of New Jersey adopted a Special Master's recommendation to partially grant Teva's motion to dismiss Mylan's antitrust lawsuit regarding Copaxone. Mylan's core Sherman Act claim survives based on allegations of a false 'Dispense as Written' campaign, exclusionary PBM agreements, and the 2020 reclassification petition/lawsuit, but claims related to citizen petitions, ANDA litigation, market shift, and copay assistance were dismissed with prejudice. The ruling allows the case to proceed on a narrower set of theories, preserving potential for future damages but reducing the scope of recovery.
Court Ruling Details
Key Facts
- Court adopted Special Master's R&R partially granting Teva's motion to dismiss Mylan's antitrust complaint
- DAW campaign, exclusionary PBM agreements, and 2020 reclassification petition/lawsuit allegations survive motion to dismiss
- 20mg citizen petitions, 20mg ANDA lawsuit, 2014 FDA lawsuit, 40mg ANDA lawsuit, market shift, and copay assistance allegations dismissed with prejudice
- Foreign allegations struck from complaint
- No damages awarded; ruling is interlocutory (motion to dismiss stage)
Financial Impact
No damages awarded at this stage. The surviving claims preserve potential for substantial damages if Mylan prevails on the merits, but the dismissed claims reduce the maximum possible recovery. The case is in early stages with no quantified exposure.
Risk Factors
- Teva may appeal the denial of dismissal on surviving claims
- Case remains in early stages; summary judgment or trial could further narrow claims
- Historical model performance on VTRS shows negative average returns at T+20, suggesting caution on near-term bullishness
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2kgjc53a-VTRS |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $16.29 $16.94 | ▲ +3.99% | ▲ +3.39% | $17.60 (+8.04%) |
Jun 25, 2026 14w ago | 144 | $16.33 $17.28 | ▲ +5.82% | ▲ +4.56% | $17.60 (+7.78%) |
Jun 18, 2026 15w ago | 8-K | $15.38 $17.29 | ▲ +12.42% | ▲ +12.57% | $17.60 (+14.43%) |
Jun 15, 2026 15w ago | 8-K | $16.04 $16.31 | ▲ +1.68% | ▲ +1.48% | $17.60 (+9.73%) |
May 13, 2026 20w ago | Court Ruling | $17.37 $16.31 | ▼ −6.10% | ▼ −5.49% | $17.60 (+1.32%) |
May 7, 2026 21w ago | 8-K | $17.39 $15.56 | ▼ −10.52% | ▼ −13.66% | $17.60 (+1.21%) |
May 4, 2026 21w ago | 8-K | $15.52 $15.69 | ▲ +1.10% | ▼ −3.86% | $17.60 (+13.40%) |
May 4, 2026 21w ago | Court Ruling | $15.20 $15.69 | ▲ +3.22% | ▼ −2.56% | $17.60 (+15.79%) |
May 4, 2026 21w ago | Court Ruling | $15.20 $15.69 | ▲ +3.22% | ▼ −2.56% | $17.60 (+15.79%) |
Apr 13, 2026 24w ago | Court Ruling | $13.83 $16.92 | ▲ +22.34% | ▲ +14.59% | $17.60 (+27.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access